Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IO102-IO103 + Pembrolizumab in First-Line Metastatic NSCLC, SCCHN, or mUBC
NCT05077709Phase 2Completed
- Sponsor
- IO Biotech
- Start
- Apr 2022
- Primary completion
- Nov 2025
- Modality
- Prophylactic Vaccines, Peptides, Peptide-based Cancer Vaccines
- Countries
- 3
01
Overview
A Phase 2 trial of PD-L1/IDO peptide vaccine in non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), Urothelial Bladder Cancer (UBC), sponsored by IO Biotech. Started Apr 2022; status: completed.
02
Drugs
PD-L1/IDO peptide vaccine
03
Conditions
non-small cell lung cancer (NSCLC)head and neck squamous cell carcinoma (HNSCC)Urothelial Bladder Cancer (UBC)
Beyond the preview
Go deeper on NCT05077709.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05077709.